PharmaJet will deliver two presentations on October 27 focusing on current and future applications of their needle-free ...
Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, ...
While anyone can contract mpox, according to the Centers for Disease Control and Prevention (CDC), those at higher risk ...
Kiniksa Pharmaceuticals International said the Food and Drug Administration has granted orphan drug designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on ...
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases ...
Rani Therapeutics secured a $1.085 billion collaboration with Chugai Pharmaceutical. Check out why I am initiating with a Buy ...
Covers low tumor burden “watch-and-wait” setting, an unmet medical needRegistrational Phase 3 watch-and-wait to start in 2026EO2463 has broad ...
RAPT Therapeutics, Inc. ( NASDAQ: RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Good morning, and welcome to RAPT's conference ...
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 ...
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback